Brief: Checkpoint Therapeutics Announces Biologics License Application Resubmission For Cosibelimab
02/07/2024 12:09
July 2 (Reuters) - Checkpoint Therapeutics Inc CKPT.O :
* CHECKPOINT THERAPEUTICS ANNOUNCES BIOLOGICS LICENSE
APPLICATION
RESUBMISSION FOR COSIBELIMAB
Source text for Eikon: ID:nGNX1XMPsg
Further company coverage: CKPT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Checkpoint Therapeutics
See all newsCheckpoint Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say